Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T. Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin J. Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew P. Grigg, Timothy P. Hughes

Research output: Contribution to journalArticle

409 Citations (Scopus)

Abstract

Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal residual disease (UMRD) by conventional quantitative polymerase chain reaction (PCR) on imatinib for at least 2 years. Patients stopped imatinib and were monitored frequently for molecular relapse. At 24 months, the actuarial estimate of stable treatment-free remission was 47.1%. Most relapses occurred within 4 months of stopping imatinib, and no relapses beyond 27 months were seen. In the 21 patients treated with interferon before imatinib, a shorter duration of interferon treatment before imatinib was significantly associated with relapse risk, as was slower achievement of UMRD after switching to imatinib. Highly sensitive patient-specific BCR-ABL DNA PCR showed persistence of the original CML clone in all patients with stable UMRD, even several years after imatinib withdrawal. No patients with molecular relapse after discontinuation have progressed or developed BCR-ABL mutations (median follow-up, 42 months). All patients who relapsed remained sensitive to imatinib re-treatment. These results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse.

LanguageEnglish
Pages515-522
Number of pages8
JournalBlood
Volume122
Issue number4
DOIs
Publication statusPublished - 25 Jul 2013

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Ross, David M. ; Branford, Susan ; Seymour, John F. ; Schwarer, Anthony P. ; Arthur, Christopher ; Yeung, David T. ; Dang, Phuong ; Goyne, Jarrad M. ; Slader, Cassandra ; Filshie, Robin J. ; Mills, Anthony K. ; Melo, Junia V. ; White, Deborah L. ; Grigg, Andrew P. ; Hughes, Timothy P. / Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease : Results from the TWISTER study. In: Blood. 2013 ; Vol. 122, No. 4. pp. 515-522.
@article{0ecb34662e904dedb1cb80de955ade92,
title = "Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study",
abstract = "Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal residual disease (UMRD) by conventional quantitative polymerase chain reaction (PCR) on imatinib for at least 2 years. Patients stopped imatinib and were monitored frequently for molecular relapse. At 24 months, the actuarial estimate of stable treatment-free remission was 47.1{\%}. Most relapses occurred within 4 months of stopping imatinib, and no relapses beyond 27 months were seen. In the 21 patients treated with interferon before imatinib, a shorter duration of interferon treatment before imatinib was significantly associated with relapse risk, as was slower achievement of UMRD after switching to imatinib. Highly sensitive patient-specific BCR-ABL DNA PCR showed persistence of the original CML clone in all patients with stable UMRD, even several years after imatinib withdrawal. No patients with molecular relapse after discontinuation have progressed or developed BCR-ABL mutations (median follow-up, 42 months). All patients who relapsed remained sensitive to imatinib re-treatment. These results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse.",
author = "Ross, {David M.} and Susan Branford and Seymour, {John F.} and Schwarer, {Anthony P.} and Christopher Arthur and Yeung, {David T.} and Phuong Dang and Goyne, {Jarrad M.} and Cassandra Slader and Filshie, {Robin J.} and Mills, {Anthony K.} and Melo, {Junia V.} and White, {Deborah L.} and Grigg, {Andrew P.} and Hughes, {Timothy P.}",
year = "2013",
month = "7",
day = "25",
doi = "10.1182/blood-2013-02-483750",
language = "English",
volume = "122",
pages = "515--522",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease : Results from the TWISTER study. / Ross, David M.; Branford, Susan; Seymour, John F.; Schwarer, Anthony P.; Arthur, Christopher; Yeung, David T.; Dang, Phuong; Goyne, Jarrad M.; Slader, Cassandra; Filshie, Robin J.; Mills, Anthony K.; Melo, Junia V.; White, Deborah L.; Grigg, Andrew P.; Hughes, Timothy P.

In: Blood, Vol. 122, No. 4, 25.07.2013, p. 515-522.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease

T2 - Blood

AU - Ross, David M.

AU - Branford, Susan

AU - Seymour, John F.

AU - Schwarer, Anthony P.

AU - Arthur, Christopher

AU - Yeung, David T.

AU - Dang, Phuong

AU - Goyne, Jarrad M.

AU - Slader, Cassandra

AU - Filshie, Robin J.

AU - Mills, Anthony K.

AU - Melo, Junia V.

AU - White, Deborah L.

AU - Grigg, Andrew P.

AU - Hughes, Timothy P.

PY - 2013/7/25

Y1 - 2013/7/25

N2 - Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal residual disease (UMRD) by conventional quantitative polymerase chain reaction (PCR) on imatinib for at least 2 years. Patients stopped imatinib and were monitored frequently for molecular relapse. At 24 months, the actuarial estimate of stable treatment-free remission was 47.1%. Most relapses occurred within 4 months of stopping imatinib, and no relapses beyond 27 months were seen. In the 21 patients treated with interferon before imatinib, a shorter duration of interferon treatment before imatinib was significantly associated with relapse risk, as was slower achievement of UMRD after switching to imatinib. Highly sensitive patient-specific BCR-ABL DNA PCR showed persistence of the original CML clone in all patients with stable UMRD, even several years after imatinib withdrawal. No patients with molecular relapse after discontinuation have progressed or developed BCR-ABL mutations (median follow-up, 42 months). All patients who relapsed remained sensitive to imatinib re-treatment. These results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse.

AB - Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal residual disease (UMRD) by conventional quantitative polymerase chain reaction (PCR) on imatinib for at least 2 years. Patients stopped imatinib and were monitored frequently for molecular relapse. At 24 months, the actuarial estimate of stable treatment-free remission was 47.1%. Most relapses occurred within 4 months of stopping imatinib, and no relapses beyond 27 months were seen. In the 21 patients treated with interferon before imatinib, a shorter duration of interferon treatment before imatinib was significantly associated with relapse risk, as was slower achievement of UMRD after switching to imatinib. Highly sensitive patient-specific BCR-ABL DNA PCR showed persistence of the original CML clone in all patients with stable UMRD, even several years after imatinib withdrawal. No patients with molecular relapse after discontinuation have progressed or developed BCR-ABL mutations (median follow-up, 42 months). All patients who relapsed remained sensitive to imatinib re-treatment. These results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse.

UR - http://www.scopus.com/inward/record.url?scp=84886917643&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-02-483750

DO - 10.1182/blood-2013-02-483750

M3 - Article

VL - 122

SP - 515

EP - 522

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -